Junshi Biosciences Submits Twelfth Indication for PD-1 Inhibitor Loqtorzi in China
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced a new indication filing...
Nanjing Sanhome’s Oritinib Ships Widely for EGFR-mutated NSCLC Treatment in China
Nanjing Sanhome Pharmaceutical Co., Ltd, a notable player in the pharmaceutical sector, has announced the...
Boehringer Ingelheim’s Zongertinib Earns Breakthrough Designation in China for HER2-Mutated NSCLC
Boehringer Ingelheim, a leading German pharmaceutical company, has received a significant endorsement from China’s Center...
China’s SAMR Proposes Antitrust Guidelines to Regulate Pharmaceutical Industry
The State Administration for Market Regulation (SAMR) in China has unveiled a draft proposal for...
IASO Biotherapeutics’ CAR-T Therapy Fucaso Gets FDA Green Light for Lupus Treatment
IASO Biotherapeutics, a Chinese biotech firm, has received Investigational New Drug (IND) approval from the...
Ascendis Pharma’s Hypoparathyroidism Therapy Yorvipath Wins FDA Nod, Fills Market Gap
This week, the U.S. Food and Drug Administration (FDA) granted market approval to Ascendis Pharma...
Siemens Healthineers Partners with Cedars-Sinai to Boost Medical Cooperation and Education
Siemens Healthineers AG, a global leader in medical technology, has announced a strategic partnership with...
Artech Medical’s Balloon Cryoablation Catheter Wins NMPA Nod for Atrial Fibrillation Treatment
Shanghai Artech Medical Technology Co., Ltd., a company known for its innovation in the medical...
Former Hainan Medical University President Li Jingquan Expelled for Serious Disciplinary Violations
Hainan’s disciplinary inspection committee has announced the expulsion of Li Jingquan, the former president of...
Pfizer’s RSV Vaccine Abrysvo Shows Strong Protection in Immunocompromised Adults, Phase III Sub-Study Reveals
Pfizer Inc. (NYSE: PFE), a pharmaceutical titan based in the US, has announced encouraging topline...
TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion
TYK Medicines Inc., a pharmaceutical company headquartered in Zhejiang, is gearing up for an initial...
Chinese NMPA Approves Hengrui Pharmaceuticals’ Generic Abraxane for Metastatic Pancreatic Cancer Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Mindray Medical Forges Comprehensive Partnership with CUHK-Shenzhen School of Medicine
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a prominent medical device company based in...
CSPC Pharmaceutical’s SYS6020 Receives NMPA Approval for Clinical Trials in Systemic Lupus Erythematosus
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company in China, has announced that...
Mabwell’s Nectin-4 Targeting ADC 9MW2821 on Path to Breakthrough Designation in China for Urothelial Carcinoma
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
Shineyo Medical Secures RMB 100 Million in Series A+ Funding for Cardiac and Vascular Devices
Shineyo Medical, a Shanghai-based manufacturer of electrophysiological and peripheral interventional devices, has reportedly secured nearly...
Fujian Cosunter’s Innovative Drug GST-HG141 Exceeds Efficacy in Reducing HBV DNA in Phase II Study
Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a Chinese pharmaceutical company, has announced the successful...
3SBio Subsidiary Achieves Milestone in Phase III Psoriasis Trial with SSGJ-608
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...
Guangdong Zhongsheng Pharmaceutical’s COVID-19 Drug Leritrelvir Approved in Macau
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a pharmaceutical company based in China, has announced...
3SBio’s Subsidiary Achieves Milestone in Phase II Study for Chronic Sinusitis Treatment SSGJ-611
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...